{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:36:01Z","timestamp":1784806561661,"version":"3.55.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hackers for Hope Pittsburgh","award":["charitable gift"],"award-info":[{"award-number":["charitable gift"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10549-022-06619-y","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T09:02:33Z","timestamp":1653123753000},"page":"393-401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy"],"prefix":"10.1007","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9391-3471","authenticated-orcid":false,"given":"Shenin A.","family":"Sanoba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7999-2804","authenticated-orcid":false,"given":"Darcy L.","family":"Thull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2933-1191","authenticated-orcid":false,"given":"Priscilla F.","family":"McAuliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer G.","family":"Steiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2155-817X","authenticated-orcid":false,"given":"Emilia J.","family":"Diego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7486-4974","authenticated-orcid":false,"given":"Phuong L.","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"key":"6619_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"key":"6619_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18.01631","volume":"37","author":"PD Beitsch","year":"2019","unstructured":"Beitsch PD, Whitworth PW, Hughes K et al (2019) Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol 37:453\u2013460. https:\/\/doi.org\/10.1200\/JCO.18.01631","journal-title":"J Clin Oncol"},{"key":"6619_CR3","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","volume":"34","author":"N Tung","year":"2016","unstructured":"Tung N, Lin NU, Kidd J et al (2016) Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol 34:1460\u20131468. https:\/\/doi.org\/10.1200\/JCO.2015.65.0747","journal-title":"J Clin Oncol"},{"key":"6619_CR4","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2402\u20132416. https:\/\/doi.org\/10.1001\/jama.2017.7112","journal-title":"JAMA"},{"key":"6619_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061598","author":"G Corso","year":"2020","unstructured":"Corso G, Montagna G, Figueiredo J et al (2020) Hereditary gastric and breast cancer syndromes related to CDH1 germline mutation: a multidisciplinary clinical review. Cancers. https:\/\/doi.org\/10.3390\/cancers12061598","journal-title":"Cancers"},{"key":"6619_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-015-3665-z","volume":"165","author":"J Ngeow","year":"2017","unstructured":"Ngeow J, Sesock K, Eng C (2017) Breast cancer risk and clinical implications for germline PTEN mutation carriers. Breast Cancer Res Treat 165:1\u20138","journal-title":"Breast Cancer Res Treat"},{"key":"6619_CR7","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1158\/1078-0432.CCR-06-0083","volume":"12","author":"N Hearle","year":"2006","unstructured":"Hearle N, Schumacher V, Menko FH et al (2006) Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 12:3209\u20133215. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0083","journal-title":"Clin Cancer Res"},{"key":"6619_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/BCTT.S111397","volume":"9","author":"SJ Howell","year":"2017","unstructured":"Howell SJ, Hockenhull K, Salih Z, Evans DG (2017) Increased risk of breast cancer in neurofibromatosis type 1: current insights. Breast Cancer Targets Ther 9:531\u2013536","journal-title":"Breast Cancer Targets Ther"},{"key":"6619_CR9","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1007\/s13277-013-0830-z","volume":"34","author":"G Zhang","year":"2013","unstructured":"Zhang G, Zeng Y, Liu Z, Wei W (2013) Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk. Tumor Biol 34:2753\u20132757. https:\/\/doi.org\/10.1007\/s13277-013-0830-z","journal-title":"Tumor Biol"},{"key":"6619_CR10","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.19.01907","volume":"38","author":"X Yang","year":"2020","unstructured":"Yang X, Leslie G, Doroszuk A et al (2020) Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol 38:674\u2013685. https:\/\/doi.org\/10.1200\/JCO.19.01907","journal-title":"J Clin Oncol"},{"key":"6619_CR11","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/JMEDGENET-2017-104588","volume":"54","author":"B Decker","year":"2017","unstructured":"Decker B, Allen J, Luccarini C et al (2017) Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks. J Med Genet 54:732\u2013741. https:\/\/doi.org\/10.1136\/JMEDGENET-2017-104588","journal-title":"J Med Genet"},{"key":"6619_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","volume":"14","author":"M Hall","year":"2021","unstructured":"Hall M, Bernhisel R, Hughes E et al (2021) Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) gene are associated with high and moderate risks for multiple cancers. Cancer Prev Res (Phila) 14:433\u2013440. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-20-0448","journal-title":"Cancer Prev Res (Phila)"},{"key":"6619_CR13","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","volume":"33","author":"G Bougeard","year":"2015","unstructured":"Bougeard G, Renaux-Petel M, Flaman J-M et al (2015) Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 33:2345\u20132352. https:\/\/doi.org\/10.1200\/JCO.2014.59.5728","journal-title":"J Clin Oncol"},{"key":"6619_CR14","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1245\/s10434-019-07341-8","volume":"26","author":"JK Plichta","year":"2019","unstructured":"Plichta JK, Sebastian ML, Smith LA et al (2019) Germline genetic testing: what the breast surgeon needs to know. Ann Surg Oncol 26:2184\u20132190. https:\/\/doi.org\/10.1245\/s10434-019-07341-8","journal-title":"Ann Surg Oncol"},{"key":"6619_CR15","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1245\/s10434-019-07549-8","volume":"26","author":"ER Manahan","year":"2019","unstructured":"Manahan ER, Kuerer HM, Sebastian M et al (2019) Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol 26:3025\u20133031","journal-title":"Ann Surg Oncol"},{"key":"6619_CR16","unstructured":"Network NCC (2020) NCCN clinical practice guidelines in oncology: breast cancer version 4.2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 12 Jun 2020"},{"key":"6619_CR17","unstructured":"Network NCC (2020) NCCN guidelines version 1.2021: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf. Accessed 12 Sep 2020"},{"key":"6619_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.2012.43.2013","volume":"31","author":"AS Reiner","year":"2013","unstructured":"Reiner AS, John EM, Brooks JD et al (2013) Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the women\u2019s environmental cancer and radiation epidemiology study. J Clin Oncol 31:433\u2013439. https:\/\/doi.org\/10.1200\/JCO.2012.43.2013","journal-title":"J Clin Oncol"},{"key":"6619_CR19","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.amjsurg.2013.08.002","volume":"206","author":"IM Lizarraga","year":"2013","unstructured":"Lizarraga IM, Sugg SL, Weigel RJ, Scott-Conner CEH (2013) Review of risk factors for the development of contralateral breast cancer. Am J Surg 206:704\u2013708","journal-title":"Am J Surg"},{"key":"6619_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2018.11.005","volume":"44","author":"D Akdeniz","year":"2019","unstructured":"Akdeniz D, Schmidt MK, Seynaeve CM et al (2019) Risk factors for metachronous contralateral breast cancer: a systematic review and meta-analysis. Breast 44:1\u201314","journal-title":"Breast"},{"key":"6619_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1221-1","author":"D Giardiello","year":"2019","unstructured":"Giardiello D, Steyerberg EW, Hauptmann M et al (2019) Prediction and clinical utility of a contralateral breast cancer risk model. Breast Cancer Res. https:\/\/doi.org\/10.1186\/s13058-019-1221-1","journal-title":"Breast Cancer Res"},{"key":"6619_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3390\/jcm7060133","volume":"7","author":"Z Xiong","year":"2018","unstructured":"Xiong Z, Yang L, Deng G et al (2018) Patterns of occurrence and outcomes of contralateral breast cancer: analysis of SEER data. J Clin Med 7:133. https:\/\/doi.org\/10.3390\/jcm7060133","journal-title":"J Clin Med"},{"key":"6619_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.surge.2014.02.005","volume":"12","author":"A Soran","year":"2014","unstructured":"Soran A, Kamali Polat A, Johnson R, McGuire KP (2014) Increasing trend of contralateral prophylactic mastectomy: what are the factors behind this phenomenon? Surgeon 12:316\u2013322","journal-title":"Surgeon"},{"key":"6619_CR24","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/S1470-2045(15)70142-7","volume":"16","author":"C Cybulski","year":"2015","unstructured":"Cybulski C, Klu\u017aniak W, Huzarski T et al (2015) Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol 16:638\u2013644. https:\/\/doi.org\/10.1016\/S1470-2045(15)70142-7","journal-title":"Lancet Oncol"},{"key":"6619_CR25","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1200\/JCO.2012.42.7336","volume":"30","author":"M Weischer","year":"2012","unstructured":"Weischer M, Nordestgaard BG, Pharoah P et al (2012) CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol 30:4308\u20134316. https:\/\/doi.org\/10.1200\/JCO.2012.42.7336","journal-title":"J Clin Oncol"},{"key":"6619_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/09553002.2017.1344363","author":"Bernstein JL, WECARE Study Collaborative Group, Concannon P","year":"2017","unstructured":"Bernstein JL, WECARE Study Collaborative Group, Concannon P (2017) ATM, radiation, and the risk of second primary breast cancer. Int J Radiat Biol. https:\/\/doi.org\/10.1080\/09553002.2017.1344363","journal-title":"Int J Radiat Biol"},{"issue":"1","key":"6619_CR27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/cancers12010140","volume":"12","author":"V Teoh","year":"2020","unstructured":"Teoh V, Tasoulis MK, Gui G (2020) Contralateral prophylactic mastectomy in women with unilateral breast cancer who are genetic carriers, have a strong family history or are just young at presentation. Cancers 12(1):140","journal-title":"Cancers"},{"key":"6619_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1245\/s10434-016-5688-z","volume":"24","author":"KK Hunt","year":"2017","unstructured":"Hunt KK, Euhus DM, Boughey JC et al (2017) Society of Surgical Oncology Breast Disease Working Group statement on prophylactic (risk-reducing) mastectomy. Ann Surg Oncol 24:375\u2013397. https:\/\/doi.org\/10.1245\/s10434-016-5688-z","journal-title":"Ann Surg Oncol"},{"key":"6619_CR29","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","volume":"93","author":"LC Hartmann","year":"2001","unstructured":"Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, Frost MH, Grant CS, Donohue JH, Woods JE, McDonnell SK, Vockley CW, Deffenbaugh A, Couch FJ, Jenkins RB (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Clin Oncol 93:1633\u20131637. https:\/\/doi.org\/10.1093\/jnci\/93.21.1633","journal-title":"J Clin Oncol"},{"key":"6619_CR30","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1245\/s10434-016-5443-5","volume":"23","author":"JC Boughey","year":"2016","unstructured":"Boughey JC, Attai DJ, Chen SL et al (2016) Contralateral prophylactic mastectomy (CPM) consensus statement from the American Society of Breast Surgeons: data on CPM outcomes and risks. Ann Surg Oncol 23:3100\u20133105. https:\/\/doi.org\/10.1245\/s10434-016-5443-5","journal-title":"Ann Surg Oncol"},{"key":"6619_CR31","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.ejso.2016.04.054","volume":"42","author":"C Boccardo","year":"2016","unstructured":"Boccardo C, Gentilini O (2016) Contralateral risk reducing mastectomy in patients with sporadic breast cancer. Benefits and hazards. Eur J Surg Oncol 42:913\u2013918","journal-title":"Eur J Surg Oncol"},{"key":"6619_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002748.pub4","author":"NE Carbine","year":"2018","unstructured":"Carbine NE, Lostumbo L, Wallace J, Ko H (2018) Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD002748.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"6619_CR33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijsu.2017.12.022","volume":"50","author":"R Kenny","year":"2018","unstructured":"Kenny R, Reed M, Subramanian A (2018) Mastectomy for risk reduction or symmetry in women without high risk gene mutation: a review. Int J Surg 50:60\u201364","journal-title":"Int J Surg"},{"key":"6619_CR34","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1200\/JCO.2007.12.3141","volume":"25","author":"TM Tuttle","year":"2007","unstructured":"Tuttle TM, Habermann EB, Grund EH et al (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25:5203\u20135209. https:\/\/doi.org\/10.1200\/JCO.2007.12.3141","journal-title":"J Clin Oncol"},{"key":"6619_CR35","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1200\/JCO.2008.20.1681","volume":"27","author":"TM Tuttle","year":"2009","unstructured":"Tuttle TM, Jarosek S, Habermann EB et al (2009) Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 27:1362\u20131367. https:\/\/doi.org\/10.1200\/JCO.2008.20.1681","journal-title":"J Clin Oncol"},{"key":"6619_CR36","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1001\/jamasurg.2017.0115","volume":"152","author":"R Nash","year":"2017","unstructured":"Nash R, Goodman M, Lin CC et al (2017) State variation in the receipt of a contralateral prophylactic mastectomy among women who received a diagnosis of invasive unilateral early-stage breast cancer in the United States, 2004\u20132012. JAMA Surg 152:648\u2013657. https:\/\/doi.org\/10.1001\/jamasurg.2017.0115","journal-title":"JAMA Surg"},{"key":"6619_CR37","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1245\/s10434-009-0547-9","volume":"16","author":"NB Jones","year":"2009","unstructured":"Jones NB, Wilson J, Kotur L et al (2009) Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution. Ann Surg Oncol 16:2691\u20132696. https:\/\/doi.org\/10.1245\/s10434-009-0547-9","journal-title":"Ann Surg Oncol"},{"key":"6619_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.breast.2018.05.001","volume":"40","author":"Q You","year":"2018","unstructured":"You Q, Chen K, Li Y et al (2018) Factors associated with the increasing trend of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ: analysis of surveillance, epidemiology, and end results data. Breast 40:147\u2013155. https:\/\/doi.org\/10.1016\/j.breast.2018.05.001","journal-title":"Breast"},{"key":"6619_CR39","first-page":"28","volume":"45","author":"JW Clerville","year":"2018","unstructured":"Clerville JW (2018) Trends of contralateral prophylactic mastectomy and other types of breast cancer surgery. J Registry Manag 45:28\u201332","journal-title":"J Registry Manag"},{"key":"6619_CR40","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1126\/science.1251827","volume":"343","author":"FJ Couch","year":"2014","unstructured":"Couch FJ, Nathanson KL, Offit K (2014) Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 343:1466\u20131470. https:\/\/doi.org\/10.1126\/science.1251827","journal-title":"Science"},{"key":"6619_CR41","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1200\/JCO.2013.53.6607","volume":"32","author":"AW Kurian","year":"2014","unstructured":"Kurian AW, Hare EE, Mills MA et al (2014) Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 32:2001\u20132009. https:\/\/doi.org\/10.1200\/JCO.2013.53.6607","journal-title":"J Clin Oncol"},{"key":"6619_CR42","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","volume":"1","author":"A Desmond","year":"2015","unstructured":"Desmond A, Kurian AW, Gabree M et al (2015) Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol 1:943\u2013951. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2690","journal-title":"JAMA Oncol"},{"key":"6619_CR43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10549-020-05699-y","volume":"182","author":"D Cragun","year":"2020","unstructured":"Cragun D, Weidner A, Tezak A et al (2020) Cancer risk management among female BRCA1\/2, PALB2, CHEK2, and ATM carriers. Breast Cancer Res Treat 182:421\u2013428. https:\/\/doi.org\/10.1007\/s10549-020-05699-y","journal-title":"Breast Cancer Res Treat"},{"key":"6619_CR44","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1245\/s10434-019-07595-2","volume":"26","author":"J Chang","year":"2019","unstructured":"Chang J, Seng S, Yoo J et al (2019) Clinical management of patients at risk for hereditary breast cancer with variants of uncertain significance in the era of multigene panel testing. Ann Surg Oncol 26:3389\u20133396. https:\/\/doi.org\/10.1245\/s10434-019-07595-2","journal-title":"Ann Surg Oncol"},{"key":"6619_CR45","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jamcollsurg.2017.12.037","volume":"226","author":"HJ Pederson","year":"2018","unstructured":"Pederson HJ, Gopalakrishnan D, Noss R et al (2018) Impact of multigene panel testing on surgical decision making in breast cancer patients. J Am Coll Surg 226:560\u2013565. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2017.12.037","journal-title":"J Am Coll Surg"},{"key":"6619_CR46","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1002\/cam4.1519","volume":"7","author":"N Elsayegh","year":"2018","unstructured":"Elsayegh N, Webster RD, Gutierrez Barrera AM et al (2018) Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Med 7:2718\u20132726. https:\/\/doi.org\/10.1002\/cam4.1519","journal-title":"Cancer Med"},{"key":"6619_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"key":"6619_CR48","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2018.13152","volume":"320","author":"J Mersch","year":"2018","unstructured":"Mersch J, Brown N, Pirzadeh-Miller S et al (2018) Prevalence of variant reclassification following hereditary cancer genetic testing. J Am Med Assoc 320:1266\u20131274. https:\/\/doi.org\/10.1001\/jama.2018.13152","journal-title":"J Am Med Assoc"},{"key":"6619_CR49","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1200\/JCO","volume":"35","author":"AW Kurian","year":"2017","unstructured":"Kurian AW, Li Y, Hamilton AS et al (2017) Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol 35:2232\u20132239. https:\/\/doi.org\/10.1200\/JCO","journal-title":"J Clin Oncol"},{"key":"6619_CR50","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1245\/s10434-017-5959-3","volume":"24","author":"JL Welsh","year":"2017","unstructured":"Welsh JL, Hoskin TL, Day CN et al (2017) Clinical decision-making in patients with variant of uncertain significance in BRCA1 or BRCA2 genes. Ann Surg Oncol 24:3067\u20133072. https:\/\/doi.org\/10.1245\/s10434-017-5959-3","journal-title":"Ann Surg Oncol"},{"key":"6619_CR51","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.amjsurg.2018.02.010","volume":"15","author":"R Morgan","year":"2018","unstructured":"Morgan R, Brown A, Hamman K, Sampson J, Naik AMK (2018) Risk management decisions in women with BRCA1 and BRCA2 mutations. Am J Surg 15:899\u2013903. https:\/\/doi.org\/10.1016\/j.amjsurg.2018.02.010","journal-title":"Am J Surg"},{"key":"6619_CR52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10689-018-0086-2","volume":"18","author":"SK Macklin","year":"2019","unstructured":"Macklin SK, Jackson JL, Atwal PS, Hines SL (2019) Physician interpretation of variants of uncertain significance. Fam Cancer 18:121\u2013126. https:\/\/doi.org\/10.1007\/s10689-018-0086-2","journal-title":"Fam Cancer"},{"key":"6619_CR53","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1186\/s12885-015-1934-1","volume":"15","author":"BK Eccles","year":"2015","unstructured":"Eccles BK, Copson E, Maishman T et al (2015) Understanding of BRCA VUS genetic results by breast cancer specialists. BMC Cancer 15:936. https:\/\/doi.org\/10.1186\/s12885-015-1934-1","journal-title":"BMC Cancer"},{"key":"6619_CR54","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.30498","volume":"123","author":"SS Buys","year":"2017","unstructured":"Buys SS, Sandbach JF, Gammon A et al (2017) A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer 123:1721\u20131730. https:\/\/doi.org\/10.1002\/cncr.30498","journal-title":"Cancer"},{"key":"6619_CR55","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.29010","volume":"121","author":"N Tung","year":"2015","unstructured":"Tung N, Battelli C, Allen B et al (2015) Frequency of mutations in individuals with breast cancer referred for BRCA 1 and BRCA 2 testing using next-generation sequencing with a 25-gene panel. Cancer 121:25\u201333. https:\/\/doi.org\/10.1002\/cncr.29010","journal-title":"Cancer"},{"key":"6619_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06581-8","author":"Y Momozawa","year":"2018","unstructured":"Momozawa Y, Iwasaki Y, Parsons MT et al (2018) Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-018-06581-8","journal-title":"Nat Commun"},{"key":"6619_CR57","unstructured":"Network NCC (2020) NCCN guidelines version 1.2020 genetic\/familial high-risk assessment: colorectal. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_colon.pdf. Accessed 19 Dec 2020"},{"key":"6619_CR58","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/tbj.12521","volume":"22","author":"T Flippo-Morton","year":"2016","unstructured":"Flippo-Morton T, Walsh K, Chambers K et al (2016) Surgical decision making in the BRCA-positive population: institutional experience and comparison with recent literature. Breast J 22:35\u201344. https:\/\/doi.org\/10.1111\/tbj.12521","journal-title":"Breast J"},{"key":"6619_CR59","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02239","author":"GD Sacks","year":"2020","unstructured":"Sacks GD, Morrow M (2020) Addressing the dilemma of contralateral prophylactic mastectomy with behavioral science. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.20.02239","journal-title":"J Clin Oncol"},{"key":"6619_CR60","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1245\/s10434-014-3747-x","volume":"21","author":"N Elsayegh","year":"2014","unstructured":"Elsayegh N, Kuerer HM, Lin H et al (2014) Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol 21:3466\u20133472. https:\/\/doi.org\/10.1245\/s10434-014-3747-x","journal-title":"Ann Surg Oncol"},{"key":"6619_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32405","author":"KA Metcalfe","year":"2019","unstructured":"Metcalfe KA, Retrouvey H, Kerrebijn I et al (2019) Predictors of uptake of contralateral prophylactic mastectomy in women with nonhereditary breast cancer. Cancer. https:\/\/doi.org\/10.1002\/cncr.32405","journal-title":"Cancer"},{"key":"6619_CR62","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1158\/1940-6207.CAPR-09-0130","volume":"3","author":"M Yi","year":"2010","unstructured":"Yi M, Hunt KK, Arun BK et al (2010) Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res 3:1026\u20131034. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-09-0130","journal-title":"Cancer Prev Res"},{"key":"6619_CR63","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1245\/s10434-011-1914-x","volume":"16","author":"A Abbott","year":"2011","unstructured":"Abbott A, Rueth N, Pappas-Varco S et al (2011) Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol 16:3129\u20133136","journal-title":"Ann Surg Oncol"},{"key":"6619_CR64","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/cge.12097","volume":"84","author":"J Culver","year":"2013","unstructured":"Culver J, Brinkerhoff C, Clague J et al (2013) Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress. Clin Genet 84:464\u2013472. https:\/\/doi.org\/10.1111\/cge.12097","journal-title":"Clin Genet"}],"updated-by":[{"DOI":"10.1007\/s10549-024-07573-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000}}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06619-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06619-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06619-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T03:03:30Z","timestamp":1736219010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06619-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,21]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["6619"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06619-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10549-024-07573-7","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,21]]},"assertion":[{"value":"6 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: Since the publication of this work, Shenin A. Sanoba has changed their name from Shenin A Dettwyler. Further, her email address has been updated to  HYPERLINK \u201cmailto:shenin.sanoba@nyulangone.org\u201d shenin.sanoba@nyulangone.org","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10549-024-07573-7","URL":"https:\/\/doi.org\/10.1007\/s10549-024-07573-7","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The project was reviewed and approved by the University of Pittsburgh Medical Center Quality Improvement Review Committee and was deemed exempt from approval by the Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This was a quality control study. The University of Pittsburgh Medical Center Quality Improvement Review Committee and Institutional Review Board has confirmed that informed consent was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable; no identifying information is included in this report or associated data, figures, or tables.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}